

# Erdafitinib alone or in combination with cetrelimab as neoadjuvant treatment (prior to surgery) in subjects with muscle-invasive bladder cancer whose tumours express FGFR gene alterations and are ineligible for receiving cisplatin treatment

<b>Submission date</b> 23/02/2023	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 25/04/2023	<b>Overall study status</b> Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 13/03/2026	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

The primary purpose of this clinical trial is to evaluate the safety and efficacy of erdafitinib (ERDA; a fibroblast growth factor receptor (FGFR)- inhibitor) alone or in combination with cetrelimab (CET; an anti-PD-1 monoclonal antibody) as neoadjuvant treatment in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC) whose tumours express FGFR gene alterations. ERDA is an experimental drug in this clinical trial and is being studied as a potential new treatment in the neoadjuvant setting of patients with non-MIBC which carry specific alterations in the FGFR family. CET is an anti-PD-1 monoclonal antibody (an immune checkpoint inhibitor (ICI)) being studied in the treatment of several tumours, including bladder cancer. A combination of CET plus ERDA seems an interesting approach in FGFR-mutated bladder cancer due to different mechanisms of action and non-overlapping toxicities, as shown in a phase II study in metastatic UC. The SOGUG Group (Sponsor) is a non-profit scientific association whose aim is to promote and develop specific programmes of study and research in the field of genito-urinary tumours.

### Who can participate?

Patients aged over 18 years old with metastatic bladder cancer

### What does the study involve?

The number of patients planned in this study is 90, with 45 in each cohort. There will be 21 study sites in 4 countries that will participate in the main study. Treatment will be assigned through a centralized allocation by order of arrival.

In the ERDA group, the patient will receive Erdafitinib (ERDA) in monotherapy neoadjuvant treatment with erdafitinib alone (cohort 1: Erdafitinib) before proceeding to radical cystectomy (RC) (to be performed within 2 - 6 weeks after the end of treatment)

In the erdafitinib (ERDA) and cetrelimab (CET) group, patients will receive treatment neoadjuvant with erdafitinib alone (cohort 2: Erdafitinib + Cetrelimab) before proceeding to radical cystectomy (RC) (to be performed within 2 - 6 weeks after the end of treatment).

When the treatment period ends, the patient will have an end-of-trial visit and an imaging and laboratory test before proceeding to surgery. The overall study duration is 60 months.

What are the possible benefits and risks of participating?

To protect the patient's safety, the study doctor will evaluate medical records, and perform physical examinations and laboratory studies to decide if the patient can participate in the clinical trial. As with all medicines, the drugs that will be used in this study may cause side effects, although not everyone will experience them. During the study, patients will be carefully monitored to detect the possible onset of these effects.

The most common side effects of each drug used in this study are indicated below. These side effects may or may not be more intense when the drugs are administered jointly. These are the risks and side effects that could be related to each drug:

1. Erdafitinib: Very Common (occurring in  $\geq 10\%$  of patients)

Higher than normal levels of phosphate in the blood; dryness of the mouth; ulcers, blisters or pain in the mouth including cheeks, tongue, or lips; diarrhoea; nail changes and disorders, including the nails, separation from the nail bed, nail pain, nail bleeding, breaking of the nails, colour or texture changes in your nails; skin problems including dryness and cracking; skin reactions with peeling, redness, swelling tingling or pain in palms of the hands and soles of the feet, called hand-foot syndrome; dryness of eyes; redness and irritation of the eye, may be associated with increased tearing of the eyes, itchy eyes, inflamed eyes; loss of hair; decreased appetite; taste disorder with food tasting sour, bitter or metallic.

Common: (occurring in  $\geq 1\%$  to  $< 10\%$  of subjects)

Eye disorders pertaining to fluid build-up under the retina (the light-sensitive layer at the back of the eye) that may or may not be associated with visual symptoms such as blurred or diminished vision or loss of vision; infected skin around the nail; itching; dryness of the nose.

Less Common (occurring in  $< 1\%$  subjects); A condition caused by calcium deposits in blood vessels, that can lead to painful red skin lesions, that may sometimes lead to open wounds, and the open wounds could become infected; skin lumps that may be skin coloured or white, soft or hard, and can become painful.

2. Cetrelimab:

Very Common (affects more than 1 user in 10):

Physical weakness and loss of strength; feeling tired or weak; shortness of breath; cough; diarrhoea (watery, loose, or soft stools); nausea; vomiting; decreased appetite; fever; pain in specific regions such as in the muscles, and bones, back, stomach, or joints; skin rash, dry skin or redness, itching; increase in liver enzymes in the blood; changes in blood levels of electrolytes (such as sodium or potassium), enzymes (such as amylase or lipase) or metabolites (such as creatinine); allergic reaction or reaction to the medicine infusion which may cause fever, chills, rash.

Common (affects 1 to 10 users in 100)

Infrequent bowel movements (constipation); changes in blood pressure (hypertension or hypotension); headache; swelling in extremities (edema); underactive thyroid gland, which can cause tiredness or weight gain, overactive thyroid gland, which can cause rapid heart rate, sweating, weight loss; high sugar levels in the blood (hyperglycemia); difficult sleeping or falling asleep (insomnia); decreased number of platelets or white blood cells; rapid heart rate (tachycardia); urinary tract infection; dizziness; nervous behaviour (anxiety); inflammation of the intestines (gastroenteritis or colitis) or stomach (gastritis) characterized by vomiting, stomach pain, constipation, dry mouth, bloody stools; dry mouth, mouth ulcers and cold sores (stomatitis); change in taste (dysgeusia); difficulty swallowing (dysphagia); indigestion (dyspepsia); blockage of the small or large bowel (intestinal obstruction); changes in weight; infections of the upper respiratory tract including bronchitis; serious lung infection (pneumonia); coughing up blood (haemoptysis); build-up of fluid in the tissues surrounding the lungs, chest cavity or abdomen (pleural effusion or ascites); inflammation of the lungs (pneumonitis), characterized by coughing and difficulty breathing, shortness of breath, chest pain; inflammation of the kidney, kidney failure, blood in urine.

The patient may experience some, none or all of these side effects and they may be mild, moderate or severe. Many of these side effects may disappear when the treatment is discontinued. In addition, there is always a risk of a very rare or previously unknown side effect occurring. The study doctor will inform the patient of any new data that may become available during the course of the study regarding the safety of the treatment.

Where is the study run from?

Spanish Oncology Genitourinary Group (Spain)

When is the study starting and how long is it expected to run for?

January 2023 to December 2029

Who is funding the study?

Janssen

Who is the main contact?

trialmanager@sogug.es

<https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-at-erdafitinib-and-cetrelimab-for-bladder-cancer-sogug-neowin>

## Contact information

**Type(s)**

Scientific

**Contact name**

Dr Trial Manager

**Contact details**

Spanish Oncology Genitourinary Group

Velázquez 7

Madrid

Spain

28001

+34 610 28 69 15  
trialmanager@sogug.es

**Type(s)**

Principal investigator

**Contact name**

Prof Syed Hussain

**ORCID ID**

<https://orcid.org/0000-0003-1552-511X>

**Contact details**

Department of Oncology and Metabolism  
Room 228, 2nd Floor, Broomcross Building  
Weston Park Hospital  
Whitham Road  
Sheffield  
United Kingdom  
S10 2SJ  
+44 (0)1142159682  
syed.hussain@sheffield.ac.uk

**Type(s)**

Public

**Contact name**

Dr Trial Manager

**Contact details**

Spanish Oncology Genitourinary Group  
Velázquez 7  
Madrid  
Spain  
28001  
+34 610 28 69 15  
trialmanager@sogug.es

## **Additional identifiers**

**Clinical Trials Information System (CTIS)**

2022-002586-15

**Integrated Research Application System (IRAS)**

1006918

**Central Portfolio Management System (CPMS)**

55028

**Protocol serial number**

## Study information

### Scientific Title

A phase II, open-label, multi-centre, multi-national interventional trial to evaluate the efficacy and safety of erdafitinib (ERDA) monotherapy and ERDA and cetrelimab combination as neoadjuvant treatment in cisplatin-ineligible patients with muscle-invasive bladder cancer whose tumours express FGFR gene alterations

### Acronym

SOGUG-NEOWIN TRIAL

### Study objectives

Primary objectives:

To assess the antitumor activity measured as pT0N0 rate, defined as no evidence of residual disease based on a pathological review of the surgical specimen

To assess the percentage of pathological downstaging response

Secondary objectives:

To evaluate the percentage of tumour downstaging

To estimate the event-free survival (EFS)

To estimate the overall survival (OS)

To evaluate the Objective Response Rate (ORR) after neoadjuvant treatment

To assess the safety profile and tolerability of both schemes

To calculate the rate of delay of surgery

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Approved 20/09/2023, North West - Greater Manchester Central Research Ethics Committee (2 Redman Place, Stratford. London. , E20 1JQ, United Kingdom; +44 (0)2071048328; gmcentral.rec@hra.nhs.uk), ref: 23/NW/0081

### Study design

Phase II open-label multi-centre multi-national interventional study

### Primary study design

Interventional

### Study type(s)

Treatment

### Health condition(s) or problem(s) studied

Muscle-invasive bladder cancer

### Interventions

Current interventions as of 02/07/2024:

Patients will receive 9 or 12 weeks of neoadjuvant treatment with erdafitinib alone (cohort 1) or

erdafitinib plus cetrelimab (CET; cohort 2) before proceeding to radical cystectomy (RC) (to be performed within 2 - 6 weeks after the end of treatment):

- ERDA (cohort 1): in monotherapy
- ERDA + CET (cohort 2): ERDA: same as in cohort 1, in combination with CET

Previous interventions as of 07/06/2024 to 02/07/2024:

Patients will receive 9 or 12 weeks of neoadjuvant (minimum 3 – maximum 4 cycles of 3 weeks each) treatment with erdafitinib alone (cohort 1) or erdafitinib plus cetrelimab (CET; cohort 2) before proceeding to radical cystectomy (RC) (to be performed within 2 - 6 weeks after the end of treatment):

- ERDA (cohort 1): in monotherapy
- ERDA + CET (cohort 2): ERDA: same as in cohort 1, in combination with CET

Previous interventions:

Patients will receive 9 or 12 weeks of neoadjuvant (minimum 3 – maximum 4 cycles of 3 weeks each) treatment with erdafitinib alone (cohort 1) or erdafitinib plus cetrelimab (CET; cohort 2) before proceeding to radical cystectomy (RC) (to be performed within 2 - 6 weeks after the end of treatment):

- ERDA (cohort 1): 8 mg (two 4 mg tablets) as a daily flat dose.
- ERDA + CET (cohort 2): ERDA: same as in cohort 1, in combination with CET: 360 mg intravenously (IV) on Cycle 1 Day 1, then every 3 weeks (21 days) thereafter (Q3W).

## **Intervention Type**

Drug

## **Phase**

Phase II

## **Drug/device/biological/vaccine name(s)**

Erdafitinib, cetrelimab

## **Primary outcome(s)**

The following primary endpoints are assessed after a maximum of 30 weeks from the start of treatment (first follow-up visit) on specimens obtained during radical cystectomy:

1. Pathological complete response (pCR), defined as the proportion of patients whose pathological staging was ypT0N0M0, measured using specimens obtained post-radical cystectomy following the study intervention
2. Pathological downstaging <ypT2, referring to patients whose pathological staging following radical cystectomy is ypT0, ypTa, ypTis or ypT1. A local pathological assessment will be done on specimens obtained during radical cystectomy (for coprimary endpoints). Thereafter, during the follow-up period, pathological assessments will be scheduled according to local standards and as clinically indicated.

## **Key secondary outcome(s)**

Current secondary outcome measures as of 04/06/2024:

1. Rate of pathological downstaging (pDS), defined as pathological TNM less than clinical TNM. [Time Frame: During treatment (27 months)]
2. Event-free survival rate. Radiographically confirmed disease progression of their cancer, death or any event that prevents the performance of RC, including initiation of any additional therapy prior to RC. Progression will be assessed using computed tomography (CT)/magnetic resonance imaging (MRI) and/or Positron Emission

Tomography (PET)-CT (per standard local imaging practices). [Time Frame: During the follow-up period (36 months)]

3. Overall survival, defined from the date of study entry until death of any cause. [Time Frame: During the follow-up period (36 months)]

4. Overall response rate, defined as the percentage of patients with partial or complete response according to RECIST v1.1 criteria. [Time Frame: During treatment (27 months)]

5. Adverse events occurring in the period from the time the patient enters the study (from the signature of consent) until 30 days after the last dose of the investigational treatment erdafitinib and until 100 days after the last dose of the investigational treatment cetrelimab [Time Frame: During treatment (27 months) and follow-up period (36 months)]

6. Rate of delay of surgery, classed as a delay event if performed > 6 weeks after last dose of treatment [Time Frame: During treatment (27 months) and follow-up period (36 months)]

Previous secondary outcome measures:

The following secondary endpoints are assessed during the treatment and follow-up period:

1. Rate of pathological downstaging (pDS), defined as patients whose pathological staging following radical cystectomy is ypT0, ypTa, ypTis or ypT1.

2. Event-free Survival rate, defined as radiographically confirmed disease progression, death or any event that prevents the performance of radical cystectomy, including initiation of any additional therapy prior to radical cystectomy. Progression will be assessed using computed tomography (CT)/magnetic resonance imaging (MRI) and/or Positron Emission Tomography (PET)-CT (per standard local imaging practices).

3. Overall survival (OS), defined as the proportion of patients who are alive at 1, 2 and 3 years, from the date of study entry until death from any cause. Progression will be assessed using computed tomography (CT)/magnetic resonance imaging (MRI) and/or Positron Emission Tomography (PET)-CT (per standard local imaging practices).

4. Overall response rate (ORR), defined as the percentage of patients with partial or complete response according to RECIST v1.1 criteria. Progression will be assessed using computed tomography (CT)/magnetic resonance imaging (MRI) and/or Positron Emission Tomography (PET)-CT (per standard local imaging practices).

5. Adverse events measured using corresponding technical depend on the adverse event. All the information will be recorded in the medical records.

6. Rate of delay of surgery, classed as a delay event if performed > 6 weeks after the last dose of treatment, measured using the rate of delay of surgery will be taken in days/weeks.

**Completion date**

31/12/2029

## Eligibility

### Key inclusion criteria

1. Written informed consent stating that he or she understands the purpose of the study and the procedures involved and agrees to participate in the study

2. Histologically confirmed diagnosis of MIBC (Stage T2-4a N0/N1 M0) obtained via a diagnostic or maximal TURBT performed no later than 3 months prior to start the screening visit

3. Pure or predominant ( $\geq 50\%$ ) UC histology as determined at the local site

4. Age  $\geq 18$  years

5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

6. Decline or ineligible ("unfit") for cisplatin-based chemotherapy

7. Presence of a selected FGFR alteration on analysis of tumour biopsy

8. Adequate organ function

- 9. No other malignancy
- 10. Willingness to avoid pregnancy or fathering children

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Mixed

**Lower age limit**

18 years

**Upper age limit**

120 years

**Sex**

All

**Total final enrolment**

0

**Key exclusion criteria**

1. Clinical evidence of N2-N3 tumours or metastatic bladder cancer
2. Has tumour with any neuroendocrine or small cell component
3. Patients who are not considered fit for cystectomy or reject cystectomy
4. Prior FGFR-targeted or antiPD1/PDL1 systemic therapy
5. Prior systemic therapy, radiation therapy, or surgery for bladder cancer

**Date of first enrolment**

01/01/2024

**Date of final enrolment**

31/03/2026

**Locations**

**Countries of recruitment**

United Kingdom

England

France

Italy

Spain

**Study participating centre**  
**Sheffield Teaching Hospitals NHS Foundation Trust**  
Room 228, 2nd Floor  
Broomcross Building  
Weston Park Hospital  
Sheffield  
England  
S10 2SJ

**Study participating centre**  
**Charing Cross Hospital**  
Fulham Palace Road  
London  
England  
W6 8RF

**Study participating centre**  
**Barts Health NHS Trust**  
Charterhouse Square  
London  
England  
EC1M 5PZ

**Study participating centre**  
**The Royal Marsden NHS Foundation Trust**  
Fulham Road  
London  
England  
SW3 6JJ

## **Sponsor information**

**Organisation**  
Spanish Oncology Genitourinary Group

**ROR**  
<https://ror.org/05f6qyf30>

## **Funder(s)**

**Funder type**

Industry

**Funder Name**

Janssen

**Results and Publications****Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Data sharing statement to be made available at a later date